← Back to all trials
Recruiting
NCT07818915
A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants
Conditions: HIV Infections
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 112
Sponsor: ViiV Healthcare
Location: GSK Investigational Site Glendale California
Summary
This study evaluates the PK, safety, and tolerability of a single increasing dose of VH4367310, a cabotegravir (CAB) prodrug, when administered intramuscularly in healthy adult participants 18 to 55 years of age.
Eligibility Criteria
Inclusion Criteria:
* Participant must be greater than or equal to (\>=) 18 years and less than or equal to (\=40 kg and BMI within the range \>=18 to \1.5x upper limit of normal (ULN). Total bilirubin \>1.5x ULN; Participants with Gilbert's syndrome can be included with total bilirubin \>1.5x ULN as long as direct bilirubin is \
Source: ClinicalTrials.gov (NCT07818915). StuddyBuddy aggregates publicly available trial information.
